Biocat

In a year made difficult by the pandemic, the life sciences and healthcare sector in Catalonia reached an exceptional milestone:€226 million in investment, the most ever in its history.

Don't miss the roundtable we have organized with ACCIÓ and CataloniaBio&Healthtech highlighting the top three 2020 investment success stories: Ona Therapeutics, Neuroelectrics and Koa Health.

Barcelona landscape

To answer this ambitious goal, we have developed the analysis 'The BioRegion of Catalonia: road to €500M in investment per year" which presents questions and answers about this possible ecosystem scaling.

Jobs Listing

The sector’s top place for job offers in Catalonia. 

BioRegion Directory

More than 1,000 companies and a wide network of universities, hospitals and research entities.

News

12.04.2021
Biocat has opened the call to take part in the 4th annual CRAASH Barcelona acceleration program, which helps researchers and entrepreneurs launch innovations in the healthtech arena to market, in collaboration with the...
01.04.2021
Biocat and Barcelona Health Hub, a private association that promotes digital health knowledge, dissemination and innovation in the capital of Catalonia, have signed a partnership agreement to promote the digital health...
25.03.2021
This year, the 15ª edición BIO-Europe Spring® event was scheduled to be held in Barcelona for the fourth time but, unfortunately, it had to move online due to the pandemic. Nevertheless, Catalonia had a strong presence...

Upcoming events

14.04.2021 to 15.04.2021
Lloc:

FYCMA (Palacio de Ferias y Congresos de Málaga)

14.04.2021 to 16.04.2021
Lloc:

Big Sight Exhibition Centre · Tokyo · Japan

START-UP GENERATION
400x400.png
11.03.2021

Antoni Matilla is the founder of the spinoff Biointaxis as well as Director of the Neurogenetics Research Unit at the Institute for Health Science Research Germans Trias i Pujol (IGTP). He is a researcher, doctor and entrepreneur with over thirty years of experience in research and business management in Catalonia, United States and United Kingdom. Since 1990, his research has focused on understanding and curing hereditary ataxias, a group of minority hereditary neurodegenerative diseases that have no cure so far.